

Original Article



Design and Evaluation of a Chalcone-Based Dimeric Scaffold Targeting Amyloid-Beta Plaques for Early Detection of Alzheimer's Disease: Synthesis, Radiolabeling, In Vivo Studies, and Integrated Molecular Docking and Dynamics Simulation

Zahra Ghiamaty¹, Mehdi Akhlaghi^{2*}, Safura Jokar^{1*}, Hooman Hafezi³, Omid Bavi³, Mohammad Sharifzadeh^{4,5}, Omid Sabzevari^{4,5}, Mehdi Shafiee Ardestani¹, Tahereh Ghorbandaeipour⁶, Mahboobeh Asadi², Mahshid Kiani¹, Sara Roustaei¹, Fatemeh Ebrahimi¹, Davood Beiki^{2*}

¹Department of Nuclear Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

²Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

³Department of Mechanical Engineering, Shiraz University of Technology, Shiraz, Iran

⁴Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

⁵Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran

⁶Department of Neurosciences and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran

Article info

Article History:

Received: October 29, 2025

Revised: April 23, 2026

Accepted: May 7, 2026

published: May 19, 2026

Keywords:

Alzheimer's disease, Chalcone, Gallium-68, Molecular imaging, PET/CT imaging, Radiolabeling

Abstract

Introduction: Amyloid-Beta (A β) plaque imaging can serve as a desirable tool for early detection of Alzheimer's disease (AD). This study presents a new dimer of a chalcone-based scaffold, [68Ga]Ga-DTPA[Ch-DE]2, as a potential radiotracer for A β plaques imaging.

Methods: The synthesis of DTPA[Ch-DE]2 and its radiolabeling with gallium-68 were characterized using techniques such as 1H-NMR, mass spectrometry, HPLC, and instant thin-layer chromatography. Neurotoxicity of DTPA[Ch-DE]2 was evaluated using the MTT assay. The stability of radiotracer was tested in various buffer systems and human serum albumin (HSA). The binding affinity of the radiotracer to A β aggregations was evaluated on the brain sections from both normal and AD rat models. Positron emission tomography-computed tomography (PET/CT) of brain imaging and Thioflavin S staining characterized the AD model. Biodistribution studies and PET/CT scans were performed on normal and AD rats. Computational studies also were conducted.

Results: [68Ga]Ga-DTPA[Ch-DE]2 was synthesized with over 93% radiochemical purity. It showed high stability in various buffer systems and HSA after 2 hours. The binding assay revealed strong affinity to A β 42 aggregations. Biodistribution studies and PET/CT imaging indicated favorable brain uptake: 0.54% ID/g and 0.59% ID/g at 2 minutes in normal and AD rats, respectively. Computational studies indicated that DTPA[Ch-DE]2 binds specifically to the A β fibrils while maintaining the receptor's architectural integrity. In vivo studies show that [68Ga]Ga-DTPA[Ch-DE]2 has good brain uptake and retention in AD rats compared with normal.

Conclusion: Thus, results suggest that [68Ga]Ga-DTPA[Ch-DE]2 could be a promising radiotracer for A β targeting and early diagnosis of AD.

Introduction

Alzheimer's disease is a progressive and irreversible neurodegenerative disorder with severe loss of memory, intellectual impairment, and behavioral disturbances that interfere with daily life.¹ It is currently the 6th leading cause of death worldwide among individuals aged over 65 years.² As the most common and deadly form of dementia, in 2022, AD dementia was estimated to affect 32.3 million

people globally. This number is expected to increase over time due to the aging population.³ With the increasing incidence of AD and its associated mortality, early and definitive diagnosis before the onset of clinical cognitive symptoms is essential to prevent irreversible neurological dysfunction.^{4,5} The two main pathological features of AD are neurofibrillary tangles (NFTs), which consist of hyperphosphorylated tau protein, and extracellular

***Corresponding Authors:** Davood Beiki, Email: beikidav@sina.tums.ac.ir; Mehdi Akhlaghi, Email: m-akhlaghi@tums.ac.ir; Safura Jokar, Email: jokars@tums.ac.ir

© 2026 The Author (s). This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.

amyloid plaques, primarily composed of A β 1-40 and A β 1-42 peptides.^{6,7} According to the reported studies, A β plaque deposition begins several years before the clinical symptoms manifest and could be considered one of the key biomarkers for identifying individuals at risk of developing AD.^{8,9} The identification of A β plaques using non-invasive nuclear imaging modalities such as PET and single-photon emission computed tomography (SPECT) could provide us with early diagnosis and differentiation of AD from other types of dementia, and the efficacy of anti-amyloid therapeutic interventions.¹⁰⁻¹²

To date, a various range of radioligands have been developed for targeting and imaging A β plaques in AD, including monoclonal antibodies,¹³ peptides,^{14,15} and small molecule derivatives, such as Congo red,¹⁶ Thioflavin T,¹⁷ and Chrysamine-G.¹⁸ Biomolecules typically exhibit limited brain penetration, slow clearance from the bloodstream, and low bioavailability.^{19,20} In contrast, small molecules demonstrate that they could be good candidates for A β plaque targeting due to more favorable cerebral pharmacokinetic properties.²¹ A variety of radiolabeled small molecules have been developed for targeting and imaging A β plaques in AD individuals. These include [¹²³I]IMPY, as a Thioflavin T derivative,²² and several PET radiotracers such as ¹¹C-Pittsburgh compound B (PIB), which is a 2-phenyl benzothiazole derivative and the first PET radioligand specifically designed for A β imaging.²³ Other PET radiotracers include [¹¹C]BF-227,²⁴ [¹¹C]SB-13,²⁵ [¹⁸F]FDDNP, an amino-naphthyl derivative,²⁶ [¹⁸F]NAV4694 (AZD4694),²⁷ [¹⁸F]GE067 (Flutemetamol/Vizamyl, a PIB analog), [¹⁸F]AV-45 (Florbetapir/Amyvid), and [¹⁸F]BAY-94-9172 (Florbetaben/NeuraCeq), which is a stilbene derivative. Among these, Florbetapir, Florbetaben, and Flutemetamol have received FDA approval for clinical use in imaging A β plaques in patients with AD.²⁸⁻³⁰ [¹²⁵I]-DMIC was reported as the first chalcone-based A β imaging probe by Ono et al in 2007.³¹

Due to the limited availability of PET cyclotron-based radionuclides such as ¹¹C and ¹⁸F in all nuclear medicine centers, there has been a growing attention toward the application of PET generator-based radionuclides, such as ⁶⁸Ga, for imaging A β plaques.³² ⁶⁸Ga could be considered as a propitious radionuclide candidate for in vivo β -amyloid plaque imaging due to its advantages such as convenient production and long-term commercial access through a ⁶⁸Ge/⁶⁸Ga generator with a long-lived (270 days), favorable emission properties (β^+ : 89%, $E_{\max}$: 1.92 MeV, $t_{1/2}$: 67.7 min), that allow prompt decay and elimination, lowering patient radiation exposure.³³

In this study, with the aim to develop a PET A β -targeting probe with optimal brain pharmacokinetics, a novel homodimeric chalcone DTPA[Ch-DE]₂ (6,9-Bis(carboxymethyl)-14-(4-((E)-3-(4-(diethylamino)phenyl)-acryloyl)phenoxy)-3-(2-(2-(4-((E)-3-(4-(diethylamino)phenyl)-acryloyl)phenoxy)ethylamino)-2-oxoethyl)-11-oxo-3,6,9,12-tetraazatetradecanoic acid) with the regarding more affinity to A β plaques than the monomeric counterpart, was prepared and radiolabeled

with [⁶⁸Ga]GaCl₃ (Figure 1). We conducted binding affinity studies of [⁶⁸Ga]Ga-DTPA[Ch-DE]₂ to A β aggregations, as well as in vivo biodistribution and imaging studies in both normal and AD rats. Furthermore, molecular docking studies and molecular dynamics simulations were performed to better understand the action mechanism and the interactions involved between DTPA[Ch-DE]₂ and A β 1-42 fibril, and monomer structures.

Materials and Methods

Materials

All chemicals and reagents were purchased from Sigma-Aldrich (Germany) and Merck and used without any purification. Thin-layer and column chromatography were performed on silica gel (SG) 60 F254 plates (Merck) and silica MN60 (60–200 μ m), respectively. Chromatographic elution solvents were acquired from Amertat Chemical Company. The A β 1–42 peptide was obtained from Sigma-Aldrich. Ketamine and xylazine were sourced from Alfasan (Netherlands). A solution of [⁶⁸Ga]GaCl₃ was eluted from a commercial ⁶⁸Ge/⁶⁸Ga generator (Pars Isotope Co., Karaj, Iran) with an activity of 110 MBq/day using 0.1 M HCl. Male Wistar rats (300–350 g) were supplied by the Royan Research Institute and kept under standard conditions (12-hour light/dark cycle at a room temperature of 20–22 °C) for further operations. The SH-SY5Y cell line was obtained from the Pasteur Institute of Iran.

Methods

DTPA[Ch-DE]₂ Synthesis and Characterization

DTPA[Ch-DE]₂ was synthesized Through a six-step reaction (Scheme 1), as previously reported.³⁴

Synthesis of Tert-Butyl 2-Bromoethylcarbamate (Compound 1).

A solution of di-tert-butyl dicarbonate (2.6 g, 12 mmol) in 25 mL of ethanol was added dropwise to a stirred mixture of triethylamine (2.76 mL, 20 mmol) and bromoethylamine hydrobromide (2.04 g, 10 mmol) in 5 mL of ethanol while cooling in an ice bath. The reaction mixture was allowed to warm to room temperature and stirred for 15 h after the addition was complete. Then,





Figure 1. Schematic representation of the suggested structure of [⁶⁸Ga]Ga-DTPA[Ch-DE]₂

Scheme 1. Chemical synthesis of the DTPA[CH-DE]₂

the solvent was evaporated under reduced pressure to yield a white solid. The solid was subsequently extracted sequentially with water (30 mL) and ethyl acetate (2 × 15 mL). The organic extracts were combined, dried over anhydrous sodium sulfate (Na₂SO₄), and the solvent was evaporated to yield compound 1 as a colorless oil (2 g, 90% yield). ¹H NMR (a Varian INOVA 500 MHz spectrometer, DMSO-*d*₆) δ 4.2 (s, 1H), 3.43 (m, 2H), 3.28 (t, *J* = 6.4 Hz, 2H), 1.37 (s, 9H), (Figure S1).

Synthesis of Para-Diethylaminobenzaldehyde (Compound 2). Diethylamine (2.9 g, 40 mmol) was first dissolved in 20 mL

of Dimethylformamide (DMF) and mixed with potassium carbonate (11.1 g, 80 mmol). Following stirring at 80 °C for 30 min, 4-fluorobenzaldehyde (4.9 g, 40 mmol) was added dropwise, and the reaction was continued at the same temperature for another 12 h. Following completion, the mixture was filtered using a sintered glass funnel, and the resulting solid was washed with ethyl acetate. Extraction was achieved using water and ethyl acetate, then the organic layer was separated, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by column chromatography of silica gel using petroleum ether/ethyl acetate as an

eluent to afford compound 2 as a yellow solid (4.4 g, 62% yield). ^1H NMR (a Varian INOVA 500 MHz spectrometer, CDCl_3) δ 9.70 (s, 1H), 7.70 (d, $J=9.1$ Hz, 2H), 6.67 (d, $J=8.6$ Hz, 2H), 3.43 (q, $J=7.0$ Hz, 4H), 1.21 (t, $J=7.1$ Hz, 6H), (Figure S2).

Synthesis of (Z)-3-(4-(Diethylamino)Phenyl)-1-(4-Hydroxyphenyl) Prop-2-en-1-One (Compound 3).

A solution of compound 2 (3.54 g, 20 mmol) in acetic acid (60 mL) was dropwise added to a stirring solution of 4-hydroxyacetophenone (2.7 g, 20 mmol) in concentrated sulfuric acid (2 mL). The reaction mixture was stirred at room temperature for 24 hours. It was then transferred into an ice bath, and the pH was adjusted to 7 with 1 M NaOH (Panpeha pH indicator strips, Aldrich Chemical Co., Darmstadt, Germany). The resulting precipitate was filtered and column chromatographed to afford compound 3 as a red powder (4.04 g, 68.5% yield). ^1H NMR (a Varian INOVA 500 MHz spectrometer, $\text{DMSO}-d_6$) δ 10.28 (s, 1H), 8.01 (d, $J=7.7$ Hz, 2H), 7.63 (d, $J=8.6$ Hz, 2H), 7.58 (d, $J=8.6$ Hz, 2H), 6.87 (d, $J=7.7$ Hz, 2H), 6.69 (d, $J=8.5$ Hz, 2H), 3.40 (q, $J=7.0$ Hz, 4H), 1.11 (t, $J=7.0$ Hz, 6H), (Figure S3), MS-EI (m/z) (a Agilent G7081B equipped with a quadrupole analyzer): $[\text{C}_{19}\text{H}_{21}\text{NO}_2]^+[\text{M}]^+$ found: 295.1; $[\text{C}_{18}\text{H}_{18}\text{NO}_2]^+[\text{M}-\text{CH}_3]^+$ found: 280.1, (Figure S4).

Synthesis of (Z)-Tert-Butyl-2-(4-(3-(4-(Diethylamino)Phenyl)Acryloyl)-Phenoxy)Ethylcarbamate (Compound 4).

To a stirred solution of compound 3 (0.88 g, 3 mmol) in acetonitrile (20 mL), potassium carbonate (2 g, 15 mmol) was added, and stirred at room temperature for 1 h. Afterward, compound 1 (tert-butyl 2-bromoethyl carbamate, 1.55 g, 7.5 mmol) was added dropwise to the reaction mixture and allowed to reflux for 12 hours. The progress of the reaction was checked by TLC. After completion, the solvent was evaporated under a vacuum, and the crude product was purified using silica gel column chromatography, yielding compound 4 as a yellow oily substance (1.03 g, 78.2% yield). ^1H NMR (a Varian INOVA 500 MHz spectrometer, $\text{DMSO}-d_6$) δ 8.10 (d, $J=8.4$ Hz, 2H), 7.65 – 7.57 (m, 4H), 7.05 (d, $J=8.5$ Hz, 2H), 6.68 (d, $J=8.5$ Hz, 2H), 4.34 (t, $J=8.1$ Hz, 1H), 4.07 (t, $J=5.8$ Hz, 2H), 3.86 (t, $J=8.1$ Hz, 1H), 3.38 (q, $J=7.0$ Hz, 4H), 1.39 (s, 9H), 1.10 (t, $J=7.0$ Hz, 6H), (Figure S5).

Synthesis of (Z)-1-(4-(2-Aminoethoxy) Phenyl)-3-(4-(Diethylamino) Phenyl) Prop-2-en-1-One (Compound 5).

A solution of compound 4 (0.65 g, 1.5 mmol) was prepared in 5 mL of dichloromethane and stirred for 30 min under an inert atmosphere of argon. In the next step, 2 mL of 25% trifluoroacetic acid (TFA) in a dichloromethane solution was added dropwise to the above solution while keeping it in an ice bath at 0°C . Afterward, the reaction mixture was stirred at this temperature for 1 h, allowed to reach room temperature, and stirred for an additional 12 h. During the work-up, the solvent was evaporated under reduced pressure until dryness. The residue was then purified by silica gel chromatography. Any impure fractions were

further purified by recrystallization: the residue was dissolved in 1 mL of methanol and slowly added to 50 mL of cold diethyl ether. The mixture was stirred in an ice bath for 6 h, which resulted in the formation of compound 5 as a yellow pure precipitate (0.31 g, 61.1% yield). ^1H NMR (Varian INOVA, 500 MHz, $\text{DMSO}-d_6$) δ 8.12 (d, $J=8.5$ Hz, 2H), 7.67–7.58 (m, 4H), 7.08 (d, $J=8.5$ Hz, 2H), 6.69 (d, $J=8.5$ Hz, 2H), 4.17 (t, $J=5.4$ Hz, 2H), 3.40 (q, $J=7.1$ Hz, 4H), 3.10 (t, $J=5.5$ Hz, 2H), 1.11 (t, $J=7.1$ Hz, 6H), (Figure S6).

Synthesis of 6,9-Bis(Carboxymethyl)-14-(4-((Z)-3-(4-(Diethylamino)Phenyl)-Acryloyl) Phenoxy)-3-(2-(2-(4-((Z)-3-(4-(Diethylamino)Phenyl)-Acryloyl) Phenoxy) Ethylamino)-2-Oxoethyl)-11-Oxo-3,6,9,12-Tetraazatetradecanoic Acid (Compound 6, DTPA[Ch-DE]₂). Diethylenetriaminepentaacetic acid bisanhydride (64 mg, 0.1 mmol) was dissolved in 8 mL of anhydrous DMF under nitrogen. Subsequently, a solution of compound 5 ((E)-1-(4-(2-aminoethoxy)phenyl)-3-(4-(diethylamino)phenyl) prop-2-en-1-one, 98 mg, 0.3 mmol) in 5 mL of dry DMF was added dropwise to the above solution. The pH of the reaction mixture was adjusted to 8 with triethylamine and stirred gently at 60°C under nitrogen. The progress of the reaction was monitored using TLC. Upon completion of the reaction, the solvent was removed under reduced pressure, and the crude product was dissolved in a minimum amount of methanol. Precipitation was initiated by adding diethyl ether. The resulting mixture underwent a liquid-liquid extraction using ethyl acetate and water. The aqueous phase was subsequently purified using a C18 reverse-phase column to remove any residual unreacted Diethylenetriaminepentaacetic acid (DTPA) and then eluted with ethanol. After evaporating the solvent, a yellow solid of compound 6 (DTPA[Ch-DE]₂) was obtained (95 mg, 94.6% yield). The MS-ESI (m/z) (Waters Synapt G1 HDMS equipped with a Q-TOF analyzer) spectrum showed the following peaks: calculated for $[\text{C}_{56}\text{H}_{71}\text{N}_7\text{Na}_3\text{O}_{12}]^{3+}[\text{M} + 3\text{Na}]^{3+}$ 1102.4837/3 = 367.4945, found: 367.1971 and calculated for $[\text{C}_{56}\text{H}_{71}\text{N}_7\text{Na}_2\text{O}_{12}]^{2+}[\text{M} + 2\text{Na}]^{2+}$ 1079.4945/2 = 539.7472, found: 540.5312. Fourier-transform infrared (FTIR) spectra were obtained using KBr pellets using a PerkinElmer Spectrum.

Radiolabeling of DTPA[Ch-DE]₂ with ^{68}Ga

To radiolabel DTPA[Ch-DE]₂ with ^{68}Ga , a fresh solution of $^{68}\text{Ga}\text{GaCl}_3$ was eluted from a sterile $^{68}\text{Ge}/^{68}\text{Ga}$ PARS-GalloGEN generator using 0.1 N HCl (3 mL). The $^{68}\text{Ga}\text{GaCl}_3$ solution was then added to a vial containing 50 μg of DTPA[Ch-DE]₂ in 420 μL of sodium acetate buffer (0.1 M, pH 7). The reaction mixture was incubated for 10 min at $70\text{--}75^\circ\text{C}$ and pH 4–4.5. The radiolabeled product was purified using a Sep-Pak C18 cartridge (Waters, Milford, MA, USA), which was treated with ethanol and activated with a 30% (v/v) ethanol-water mixture. To remove any free ^{68}Ga , the column was rinsed with 5 mL of deionized water. $^{68}\text{Ga}\text{Ga-DTPA[Ch-DE]}_2$ was eluted using 1 mL

of 50% (v/v) ethanol-water mixture. Finally, to ensure sterilization and eliminate any colloidal impurities, the final product was filtered through a 0.22-micron filter (Merck Millipore, Darmstadt, Germany). ITLC (SG, Merck, Darmstadt, Germany) and HPLC (a Agilent 1200 with a C18 column 4.6×250 mm, 5 µm coupled with a UV detector $\lambda=254$ nm) were utilized to determine radiolabeling efficiency and radiochemical purity. For ITLC, we employed a 1.5 cm wide silica gel chromatography paper (ITLC-SG), and a 1:1 mixture of methanol and 1 M ammonium acetate as the mobile phase using a TLC scanner (MiniGita, RAYTEST, Germany). Radiochemical purity was assessed by reverse phase HPLC (Agilent 1200 on a C18 column 4.6×250 mm, 5 µm) with a gradient elution program, which was equipped with a sodium iodide NaI(Tl) detector (RAYTEST, Straubenhardt, Germany). The mobile phase consisted of water (A) and acetonitrile (B) with 0.1% TFA. The gradient elution was performed in the following sequence: 0-2 min with 100% A, 2-4 min with 25% B, 4-6 min with 50% B, and 6-25 min with 100% acetonitrile, at a flow rate of 1 mL/min.

Determination of Partition Coefficient (Log P)

To determine the n-octanol/PBS partition coefficient (Log P), the radiotracer (100 µL, 3.7 MBq) was added to a vial containing 1.5 mL of n-octanol and 1.5 mL of PBS (0.1 M, pH 7.4). The mixture was vigorously vortexed at room temperature for 10 min and then centrifuged at 3500 rpm for 5 min to achieve complete phase separation. Equal volumes of each phase (500 µL) were then measured for radioactivity using a gamma counter. Log P was determined as the logarithmic ratio of n-octanol phase counts to PBS phase counts.

In-Vitro Stability of Radiotracer

The stability of [^{68}Ga]Ga-DTPA[Ch-DE]₂ was evaluated by incubating the radiotracer (100 µL, 3.7 MBq) at 37 °C in separate vials containing 1 mL of different solutions: 0.1 M PBS (pH 7.4), normal saline (pH 5.5), and HSA. To test serum stability, blood was drawn from a healthy volunteer and allowed to clot at 37 °C for 45 min. The radiochemical purity was evaluated at different times (15 to 120 min) using TLC.

Cytotoxicity Assay

The neurotoxicity of the synthesized chalcone was evaluated on the SH-SY5Y human neuroblastoma cell line, as previously reported.³⁵ The SH-SY5Y cells were seeded in 96-well plates at a density of 3×10^4 cells/well and incubated for 24 h. Following 24 h, the culture medium was refreshed with a new medium consisting of various concentrations of the chalcone (a range from 5 to 250 µg/mL), and incubated for 24 h and 48 h at 37 °C. After incubation, the culture medium was removed, and 50 µL of MTT solution (0.5 mg/mL in PBS) was added to each well and allowed to incubate for 4 h at 37 °C in the dark. The resulting crystals were dissolved in 100 µL DMSO and gently shaken for 15 min. The absorbance was

recorded at 570 nm using a microplate reader (INFINITE M1000).

In-Vitro Amyloid Binding Assay

For A β 1-42 aggregation preparation, 0.1 mg lyophilized peptide was dissolved in 1 mL of phosphate buffer solution (10 mM sodium phosphate, 1 mM EDTA, pH 7.4) and incubated at 37 °C for 42 h with shaking. For binding assays, PBS (900 µL), A β 1-42 aggregates (30 nM, 100 µL), and different radiotracer concentrations (0.5–100 nM, 100 µL) were incubated for 2 h at room temperature in borosilicate glass vials. Nonspecific binding was defined by co-incubation using a 100-fold molar excess of nonradioactive chalcone as a blocking agent. Samples were filtered through filters 0.22 µm, washed with 5 mL of 10% ethanol to remove the free radiotracer, and the remaining activity on the filters was counted with a gamma counter. Specific binding was determined by the subtraction of total from nonspecific binding. The maximum binding capacity (B_{max}) and dissociation constant (K_d) were determined by nonlinear regression using GraphPad Prism 9.5.1.

AD Model Development and Characterization

The animal studies were performed under national guidelines for animal research and received approval Code: IR.TUMS.TIPS.REC.1398.172 from the ethical committee at Tehran University of Medical Sciences Research.

The AD model was induced in Male Wistar rats (300–350 g) through stereotaxic surgery with a stereotaxic apparatus (Stoelting, USA).³⁶ The rats were anesthetized by intraperitoneal injection of a ketamine/xylazine mixture (70 mg/kg and 10 mg/kg, respectively) and positioned in a stereotaxic frame. The dorsal scalp was shaved and incised to expose the skull. After cleaning, the Bregma and Lambda landmarks were identified, and the stereotaxic coordinates of the CA1 region of the hippocampus were determined according to the Paxinos and Watson rat brain atlas: anteroposterior (AP) = -3.2 mm, mediolateral (ML) = +1.5 mm, and dorsoventral (DV) = -2.7 mm.³⁷ 2 µL of aggregated A β (1 µg/site) or PBS (sham group) was injected intracerebrally into all rats using a Hamilton microsyringe. The incision was then sutured, and animals were kept under standard laboratory conditions (25 °C, 12 h light/dark cycle) in the Comprehensive Research Laboratory of Tehran University of Medical Sciences for further evaluation. To confirm AD induction, the cerebral glucose metabolism of the animals was evaluated using FDG-PET imaging. Briefly, the animals were fasted for 24 h before imaging and then injected with 26 MBq of FDG in 250 µL of normal saline via the tail vein. After a 45-minute uptake period, the animals were anesthetized, and PET scans were obtained over a 10-minute interval. Moreover, the presence of A β aggregations in the brain tissues of the animals was assessed using Thioflavin S Staining. The brains were excised and fixed with 10% formaldehyde following cardiac perfusion to complete depletion of blood. The fixed tissues were sectioned into 5 µm slices by a microtome. The slides were incubated in a

0.5% Thioflavin S solution prepared in 0.1 N hydrochloric acid (Sigma, England) for 10 minutes in a humid, dark chamber. Afterward, they were stained and then rinsed with 50% ethanol, followed by distilled water. The A β plaques were then viewed under an Olympus IX71 fluorescence microscope (Japan).

MicroPET Imaging of Brain Tissue

To assess the presence of A β aggregations and binding affinity of the [^{68}Ga]Ga-DTPA[Ch-DE]₂ to them, the brain sections from both normal and AD rat models with a thickness of 5 μm were prepared using a microtome and fixed on glass slides. The brain sections were incubated with the radiotracer (100 μL , 3.7 MBq) for 30 minutes at room temperature. Following incubation, any free and nonspecifically bound radiotracers were removed by washing the sections with 40% ethanol and then deionized water. The brain sections were subsequently dried and imaged using microPET (Xtrim PET, Parto Nefar Persia Co., Iran) for 15 min.

Biodistribution Studies and PET/CT Imaging

The biodistribution studies of the [^{68}Ga]Ga-DTPA[Ch-DE]₂ were performed in AD and normal rats to evaluate the brain uptake, excretory pathways, and accumulation in non-target organs. The radiotracer (9.25 MBq, 250 μL) was injected into all of the animals via the tail vein. The animals were euthanized 2, 30, and 60 min post-injection. The target organs were then removed, rinsed with cold saline, weighed, and counted with a γ -counter. The results were expressed as the percentage of injected dose/gram (% ID/g). Additionally, the uptake in the removed organs was assessed using PET imaging with a 10-minute acquisition and subsequent drawing of regions of interest (ROI).

A whole-body PET/CT scan of AD and normal rats was performed using a PET/CT scanner (Biograph 6, Siemens Medical Solutions, Erlangen, Germany). The animals were intravenously injected with [^{68}Ga]Ga-DTPA[Ch-DE]₂ and florbetapir (9.25 MBq, 250 μL) as a reference radiotracer, and anesthetized using a ketamine/xylazine mix. Dynamic PET imaging was then acquired for about 20 minutes on the prone-positioned animals. CT scanning was also performed to localize anatomy and attenuation correction (20 seconds, 80 kV, 150 mAs, 1.25 mm spatial resolution). PET images were reconstructed using a filtered back-projection algorithm and co-merged with match-associated CT images.

Statistical Analysis

All values were reported as mean $\pm$ standard deviation (SD) and statistical analysis was performed by student t-test or one-way ANOVA using GraphPad Prism 9.5.1 software. Values of $P < 0.01$, $P < 0.001$, and $P < 0.0001$ were considered statistically significant in all experiments.

Molecular Docking

To perform molecular docking studies, the 3D structure of the A β 1-42 fibril (code: 2BEG) and A β 1-42 monomer

(code: 1IYT) was taken from the website RSCB (<http://www.rcsb.org/>). Briefly, some processes were performed on the 3D structures, including the deletion of water molecules and other isoforms using UCSF Chimera software, adding hydrogen atoms, determination of bond orders, optimization, and energy minimization with the GROMOS96 implementation by Swiss-PDB Viewer version 19 3.7 software. The 2D structures of DTPA[Ch-DE]₂ and florbetapir, PIB compound as the reference ligands, were prepared by ChemSketch software and minimized using the HyperChem 8.0 program with molecular mechanics (RMSD 0.01 Å and AMBER force field) and semi-empirical (PM3) techniques. Subsequently, they were saved in pdb format. Finally, polar hydrogen atoms and charge were added to their structures in order to optimize the energy of the compounds and were saved in pdbqt format using the Autodock tool software.

Molecular docking was performed using Autodock Vina software to obtain the optimized conformations.³⁸ Briefly, DTPA[Ch-DE]₂ and florbetapir, PIB compound were docked on the 3D structure of the A β 1-42 fibril and A β 1-42 monomer with grid boxes dimensions of 126 Å, 80 Å and 88 Å, grid spacing 0.375 Å, and coordinate X = -1.306, Y = 0.028, and Z = 1.083 for the A β 1-42 fibril and monomers. AutoDock Tools and LigPlot⁺ were used to visualize the ligand-target interactions.

Molecular Dynamics Simulation

The molecular dynamics (MD) simulations were performed using NAMD 3.0, leveraging GPU acceleration and the CHARMM36 force field to model atomic interactions. Trajectory visualization and analysis were performed with Visual Molecular Dynamics (VMD), following established methodologies.³⁹ The 3D structure of DTPA[Ch-DE]₂ was built using ChemSketch and optimized at the PM3 semi-empirical level in HyperChem. CHARMM36-compatible parameters were generated using the CHARMM General Force Field (CGenFF) program (version 4.6) via the CGenFF web interface. Missing bond, angle, dihedral, and improper parameters were assigned by analogy with chemically similar fragments within CGenFF. Penalty scores were all below 20, indicating good parameter quality. Each receptor was embedded in a TIP3P water box (dimensions: 81 $\times$ 61 $\times$ 67 Å) and subjected to energy minimization via the steepest descent method.^{40,41} System equilibration was confirmed by monitoring the RMSD and total energy, which reached stable values after 100 ns. For robust statistical analysis, three independent 100-ns simulations were run for each receptor-ligand complex, and data were averaged over the equilibrated trajectory segments. Ligands were incorporated into pre-equilibrated receptor structures, after which the systems underwent further energy minimization and equilibration.

Temperature control (310 K) was achieved with a Langevin thermostat, while pressure was stabilized using a Nosé-Hoover barostat. Electrostatic interactions at long range were evaluated via the PME method, applying a 12 Å cutoff distance and 1 Å grid spacing.⁴² Analytical

assessments utilized trajectory data from the final 100 ns. Binding free energies and interaction forces were derived using a custom Tcl script, while structural stability was evaluated through the Radius of Gyration (RoG) and Root Mean Square Fluctuation (RMSF) measurements. These metrics offered insights into receptor compactness, flexibility, and conformational dynamics during ligand interactions.^{5,43}


Results and Discussion

Alzheimer's disease is considered the most prevalent form of dementia, with approximately 55–60% of all dementia cases in the elderly. Regarding the increasing 48.2% risk of AD in individuals over 95 years old, without any potential cure, there will be socio-economic concerns for the healthcare system in the future.⁴⁴ Early diagnosis of AD could result in potentially therapeutic interventions and slowing down the disease process, and reducing the social and economic burden on healthcare systems.^{4,5} With this aim, numerous radiotracers have been evaluated for targeting and imaging of A β plaques. Small organic molecules, among them, are promising tracers for imaging A β owing to their preferred properties.^{21,28–30} Chalcones have several mechanisms against AD, including targeting and binding tightly to A β plaques, and inhibition of A β fibril deposition and the action of enzymes such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and pseudocholinesterase.^{45–48} These multifaceted interactions contribute to the development of the chalcone-based scaffolds as a promising strategy for the diagnosis and therapy of Alzheimer's disease.

Synthesis of DTPA[Ch-DE]2

It has been illustrated in previous studies that the introduction of an electron-donating group at the R₂ position of chalcone derivatives was observed to increase their binding affinity against A β plaques (Scheme 2).^{31,49} Additionally, the introduction of various aromatic substituents at the R₂ position has been observed to enhance lipophilicity, thereby providing improved permeability across the BBB. Since planarity of the ligand is a critical requirement for fitting within the hydrophobic pockets of the β -sheet structures of A β plaques, the incorporation of aromatic groups in the chalcone backbone ensures the retention of this planar conformation for optimal interaction.^{50,51}

Based on this concept, we designed DTPA[Ch-DE]₂, a scaffold consisting of a dimer of chalcone with a core DTPA, which acts as a chelator for radiolabeling with [⁶⁸Ga]GaCl₃. This design aims to enhance the binding affinity to A β plaques. Molecular docking and MD simulation studies demonstrated that the presence of two chalcone units symmetrically positioned on either side of the



Scheme 2. Chalcone synthesis via aldol condensation reaction

DTPA molecule could improve binding of the compound to several sites along the β -sheet regions of A β aggregates. Besides, The chalcone derivative synthesized in our study (DTPA[Ch-DE]₂) has a higher binding affinity to amyloid beta plaques than previous similar works (DTPA[Ch-DM]₂),³⁴ as evident from docking studies in vitro test results (binding affinity energy (kcal/mol): -5.7 and -5.2 for DTPA[Ch-DE]₂ and DTPA[Ch-DM]₂, respectively. In this study, we strategically introduced an aromatic group with an electron-donating substituent at position R₂ and a phenolic group at position R₁ to facilitate subsequent amination and conjugation to DTPA.

The DTPA[Ch-DE]₂ compound was successfully synthesized and purified by RP HPLC to yield a yellow solid with a purity of greater than 95%, as presented in Figure S7. The molecular identity of the DTPA[Ch-DE]₂ was determined by mass spectrometry. The peaks found at m/z: 540.53 ([M+2Na]²⁺) and m/z: 367.19 ([M+3Na]³⁺) in the mass spectrum confirm the expected molecular structure (Figure S8). Moreover, comparative IR spectroscopy conducted before and after DTPA conjugation confirmed successful chelation, as evidenced by spectral shifts (Figure S9). In the IR spectrum of compound 6, the broad absorption band observed at 3427.6 cm⁻¹ corresponds to the O–H stretching vibrations of the carboxylic acid functional group. Additionally, the broadband at 1739.6 cm⁻¹ is attributed to the stretching vibrations of the carbonyl group of the carboxylic acid moiety within the compound's structure. Furthermore, a band at 1623.5 cm⁻¹ can be assigned to the amide carbonyl (C=O) stretching vibrations. These spectral features confirm the successful conjugation of compound 5 to the DTPA chelator.

Radiolabelling of DTPA[Ch-DE]2 with [⁶⁸Ga]GaCl3

⁶⁸Ga was selected as an appropriate PET radioisotope for radiolabeling DTPA[Ch-DE]₂ due to its desirable physicochemical characteristics and convenient availability through the ⁶⁸Ge/⁶⁸Ga generator, in contrast to ¹⁸F, which is produced using a cyclotron. In vivo stability of metal complexes and the lack of metal ion release has a vital role in the selection of a chelator. According to the Hard and Soft Acids and Bases (HSAB) principle, Ga³⁺ is considered as a hard Lewis acid and tends to form more stable complexes with hard Lewis bases, such as nitrogen atoms in amines and hydroxyl groups in carboxylic acids.⁵² Additionally, the timing of the radiolabeling reaction is crucial because of the short half-life of ⁶⁸Ga. Studies have shown that linear chelators have a faster complexation rate compared to cyclic analogs due to their structural flexibility and improved reaction kinetics, which allows for the formation of neutral complexes that can permeate the BBB.^{53,54} DTPA is an effective octadentate acyclic chelator most commonly used in chelation chemistry. It is efficiently capable of coordinating Ga³⁺ under mild conditions to form thermodynamically stable complexes.⁵³ The optimal condition for radiolabeling was evaluated under various temperatures (R.T. to 90 °C) and pH

conditions (1 to 7). The best efficiency of radiolabeling was achieved at a temperature of 70–75 °C and a pH range of 4.0–4.5. Under these optimum conditions, [^{68}Ga]Ga-DTPA[Ch-DE]₂ was obtained with a radiochemical yield of 87%, a molar activity (Am) of 13.07 MBq/nmol, and radiochemical purity of more than 93%, which was achieved by purification on a Sep-Pak C18 column. As shown in the HPLC chromatogram, the retention times are 0.87 and 20 min for free ^{68}Ga and [^{68}Ga]Ga-DTPA[Ch-DE]₂, respectively (Figure 2A). Moreover, ITLC data shows retention factors (R_f) at 0.1 and 0.7, which are related to colloid forms of ^{68}Ga and [^{68}Ga]Ga-DTPA[Ch-DE]₂, respectively (Figure 2B).

n-Octanol/PBS Partition Coefficient (Log P)

The lipophilicity of [^{68}Ga]Ga-DTPA[Ch-DE]₂ was obtained using measurement of its *n*-octanol/PBS (pH 7.4) partition coefficient at room temperature. The resultant log P value was calculated as 2.05 ± 0.14 (mean $\pm$ SD, $n=3$), which demonstrates a lipophilic nature of ^{68}Ga -DTPA[Ch-DE]₂. Since the optimal window of lipophilicity (log P) of the brain radiotracers is typically 1.0 to 3.0, which is a criterion to effectively penetrate the BBB,¹⁵ The [^{68}Ga]Ga-DTPA[Ch-DE]₂ could be a good radiotracer for brain imaging.

Stability Studies

The stability of [^{68}Ga]Ga-DTPA[Ch-DE]₂ was evaluated in

normal saline (pH 5.5), PBS (0.1 M, pH 7.4), and human serum at 37 °C for 120 min. The radiochemical purity was monitored at various time intervals using ITLC-SG with a 1:1 mobile phase consisting of 1 M ammonium acetate and methanol. The radiotracer demonstrated high stability (>90%) in saline, PBS, and human serum within the 120-min period (Figure 3A and 3B).

In-Vitro Binding Assay

The binding affinity of [^{68}Ga]Ga-DTPA[Ch-DE]₂ to A β aggregation was evaluated through performing total and nonspecific binding studies of [^{68}Ga]Ga-DTPA[Ch-DE]₂ on A β peptide aggregation. The values of K_d and B_{max} were obtained as 3.74 ± 0.84 nM and 13649 ± 460.49 bound molecules/plaque, respectively (Figure 3C). The binding affinity of [^{68}Ga]Ga-DTPA[Ch-DE]₂ falls within the previously reported K_d range of 3.4–6.5 nM for the chalcone-derived A β -targeting agents,⁴⁵ which confirms the strong binding affinity of [^{68}Ga]Ga-DTPA[Ch-DE]₂ to A β aggregation.

Cytotoxicity Assay

The cytotoxicity of DTPA[Ch-DE]₂ was investigated against the SH-SY5Y neuroblastoma cell line at concentrations ranging from 5 to 250 $\mu\text{g/mL}$ for 24 and 48 h after incubation using the MTT assay. As displayed in Figure 3D, no statistically significant cytotoxic effects were observed in the SH-SY5Y cell line at concentrations lower than 250 $\mu\text{g/mL}$. Meanwhile, the concentration of DTPA[Ch-DE]₂ used in each injection dose of animal studies is much lower than these values.

Animal Models Development

After injection of A β 1-42 aggregation into the hippocampus region of animals, the Alzheimer's model was confirmed using in vivo brain imaging with [^{18}F]-FDG-PET to assess changes in glucose metabolism. Additionally, in vitro Thioflavin S staining on brain tissue sections from both AD and normal rats was performed to visualize A β aggregation. The Thioflavin S staining confirmed the presence of A β fibril aggregation within the AD model compared to normal animals, the Alzheimer's group revealed 86.3% plaque staining, whereas the normal revealed merely 19.4% ($P < 0.0001$, Figure 4A and 4B). Furthermore, the results of [^{18}F]-FDG-PET imaging demonstrate that there is reduced brain uptake of FDG in the Alzheimer's model compared to the normal animals (Figure 4C and 4D), which confirmed AD induction.

MicroPET imaging of Brain Tissue Sections

To further validate the presence of A β aggregations and binding affinity of [^{68}Ga]Ga-DTPA[Ch-DE]₂ to A β plaques, ex vivo microPET imaging was performed on brain sections from AD and normal rats using microPET after 30-min incubation with radiotracer. The findings showed a significant accumulation of [^{68}Ga]Ga-DTPA[Ch-DE]₂ in brain tissues of Alzheimer's rats compared to normal rats (Figure 5).




Figure 2. Radiochemical purity of [^{68}Ga]Ga-DTPA[Ch-DE]₂; **A)** HPLC profile of [^{68}Ga]Ga-DTPA[Ch-DE]₂; the peaks at 0.87 and 20 min are related to free ^{68}Ga and [^{68}Ga]Ga-DTPA[Ch-DE]₂, respectively. **B)** ITLC analysis, retention factors at 0.1 and 0.7 are for colloid forms of ^{68}Ga and [^{68}Ga]Ga-DTPA[Ch-DE]₂, respectively




Figure 3. Stability studies of $[^{68}\text{Ga}]\text{Ga-DTPA[Ch-DE]}_2$ in **A**) PBS (pH=7.4), NS (pH=5.5), and **B**) HSA at 37°C up to 120 min; **C**) Saturation curve for binding of $[^{68}\text{Ga}]\text{Ga-DTPA[Ch-DE]}_2$ to A β aggregation; **D**) Cytotoxicity assay of DTPA[Ch-DE] $_2$ on the SH-SY5Y neuroblastoma cell line after 24 hours and 48 hours of incubation. Cells were treated with 5, 25, 50, 100, and 250 $\mu\text{g/mL}$ of DTPA[Ch-DE] $_2$, and cell viability was evaluated by using the MTT test. (mean $\pm$ SD, n = 3)




Figure 4. **A**) Thioflavin S staining of A β plaques in rat brain tissue sections from Hippocampus **a**) normal **b**) AD; **B**) Statistical analysis of thioflavin S% bound to A β plaques between normal and AD groups (n=3); While $P < 0.0001$ indicates a significant difference in the intensity of thioflavin staining between the Alzheimer's and normal groups. **C**) $[^{18}\text{F}]\text{FDG}$ -PET/CT images taken in sagittal and coronal views in **a**) normal, **b**) AD rat; **D**) Brain uptake of radioactivity (% ID/g) after injection of $[^{18}\text{F}]\text{FDG}$ in normal and AD rats

Biodistribution and Imaging Studies

According to the obtained in vitro findings, we are encouraged to perform biodistribution studies of

$[^{68}\text{Ga}]\text{Ga-DTPA[Ch-DE]}_2$ in AD and normal rats. The biodistribution studies of $[^{68}\text{Ga}]\text{Ga-DTPA[Ch-DE]}_2$ in normal and AD rats were performed at 2, 30, and 60 min

post-injection. As shown in Figure 6, there is a higher brain uptake and slower washout rate in AD rats than in normal rats. The brain uptake of ^{68}Ga -DTPA[Ch-DE]₂ was similar in both groups, with values of $0.54 \pm 0.34\%$ and $0.59 \pm 0.55\%$ ID/g at 2 min post-injection for normal and AD rats, respectively. However, over time, the ^{68}Ga -DTPA[Ch-DE]₂ was washed out rapidly from the brain of normal rats than from ADs due to the presence of A β plaques. There is a significant difference ($P < 0.0001$) in the amount of brain uptake of ^{68}Ga -DTPA[Ch-DE]₂ at 30 and 60 min post-injection between two groups. The brain uptake of ^{68}Ga -DTPA[Ch-DE]₂ after 30 min (0.26% ID/g) is comparable with other chalcone-derived radiotracers previously reported, such as ^{68}Ga -

DT(Ch)₂ (1.24% ID/g)³⁴ [$^{99\text{m}}\text{Tc}$]-DT(Ch)₂ (1.16% ID/g)⁵⁵ [^{18}F]-DMFC (4.43% ID/g), [^{18}F]-MC (5.42% ID/g), [^{125}I]-DMIC (2.43% ID/g), [^{125}I]-IMC (3.52% ID/g).⁵⁶ Moreover, an initial high uptake was observed in several organs, including the liver, kidneys, lungs, and intestines. Furthermore, the brain uptake of ^{68}Ga -DTPA[Ch-DE]₂ in normal rats was obtained at 2 and 30 minutes post-injection and was compared with the brain uptake of [^{18}F]-Florbetapir as reported in previous studies (Table 1). Figure 7 presents PET/CT imaging obtained 30 min after injection of ^{68}Ga -DTPA[Ch-DE]₂ and [^{18}F]-Florbetapir in animals. Due to the lipophilicity of ^{68}Ga -DTPA[Ch-DE]₂ and florbetapir, both of them showed prominent liver uptake; however, florbetapir, due to its relatively higher lipophilicity, shows predominant excretion in the hepatobiliary pathway. In contrast, ^{68}Ga -DTPA[Ch-DE]₂ showed double excretion routes, hepatobiliary and renal, which is also the reason for the accumulation of activity in the kidney as reported for other ^{68}Ga -chalcone-derived radiotracers.³⁴ The kidney uptake




Figure 5. MicroPET images of ^{68}Ga -DTPA[Ch-DE]₂ in A) normal, and B) AD rat brain sections

Table 1. Brain uptake of ^{68}Ga -DTPA[Ch-DE]₂ and [^{18}F]-Florbetapir in normal rats 2 min and 30 min post-injection

Compound	%ID/g Brain		Ratio (2 min / 30 min)
	2 min	30 min	
^{68}Ga -DTPA[Ch-DE] ₂	0.54 ± 0.34	0.26 ± 0.22	2.07
[^{18}F]-Florbetapir	4.9 ± 0.99	1.65 ± 0.11	$2.96^{†, 50}$

†: Reference 50




Figure 6. In-vivo biodistribution studies of ^{68}Ga -DTPA[Ch-DE]₂ (as %ID/g, Mean $\pm$ SD, $n=3$) in A) normal rat, B) AD rat, C) Statistical analysis of the brain uptake of ^{68}Ga -DTPA[Ch-DE]₂ between normal and AD rats at 2, 30, and 60 min post-injection, and D) PET/CT images of the removed organs from the AD rat after 30 min post-injection

may be related to polar metabolites of the ^{68}Ga -DTPA[Ch-DE]₂. As shown in Figure 7, both radiotracers [^{68}Ga]Ga-DTPA[Ch-DE]₂ and [^{18}F]-Florbetapir showed detectable brain uptake in AD rats. One of the challenges of gallium-labeled radiopharmaceuticals is their limited ability to pass through the blood-brain barrier due to their inherent hydrophilic nature.⁵⁷⁻⁵⁹ In the current study, the chalcone dimer was used due to the placement of the DTPA in the middle, which, in addition to enabling labeling, also caused the addition of two lipophilic arms on both sides of the molecule, which increased their lipophilicity and the ability to enter the brain. Although the brain uptake of [^{68}Ga]Ga-DTPA[Ch-DE]₂ was comparatively lower compared to florbetapir, this small amount of brain entry is desirable and considered a success for gallium-labeled radiopharmaceuticals.

One of the most critical requirements for a successful brain imaging agent is the ability to penetrate well through the BBB, deliver an appropriate level of radioactive to the brain, and clear rapidly from normal, beta-amyloid-free areas, to give a good signal-to-noise ratio. Dynamic PET/CT imaging was performed for 20 min post-injection of [^{68}Ga]Ga-DTPA[Ch-DE]₂ in AD rats to evaluate blood-brain barrier (BBB) permeability and brain pharmacokinetics. The results of dynamic imaging in Alzheimer's rats demonstrated an increase in brain uptake with a slow clearance rate (Figure 7B). The findings are evidence for the feasibility of [^{68}Ga]Ga-DTPA[Ch-DE]₂ to image A β aggregates in vivo.

Molecular Docking

Docking studies were performed to evaluate the interactions of DTPA[Ch-DE]₂, DTPA[Ch-DM]₂, PIB, and florbetapir compounds as reference ligands with both the A β monomer and fibril. The obtained values of binding energies in the best-docked conformation (lowest

energy values) were summarized in Table 2. DTPA[Ch-DE]₂ revealed a strong binding affinity to A β 42 fibril with a binding energy of -5.7 kcal/mol compared to DTPA[Ch-DM]₂ at -5.2 kcal/mol, PIB at -5.0 kcal/mol, and florbetapir at -4.0 kcal/mol.

DTPA[Ch-DE]₂ demonstrated a strong binding mode with A β fibrils using a combination of the hydrophobic interactions with several amino acid residues, including Gly37, Gly38, Val36, Val39, Val40, Met35, Leu17, and Phe19, along with a hydrogen bond formed with Gly37 (Figure 8). These findings indicate that DTPA[Ch-DE]₂ has a good binding capacity towards A β plaques.

Molecular Dynamics Simulation

The thermodynamic and structural behavior of ligand-receptor complexes was analyzed through MD simulations. The interaction energies, force distributions, and structural dynamics were compared for the AV-45 and DTPA[Ch-DE]₂. Figure 9A presents the average non-bonded interaction energies—comprising electrostatic and van der Waals components—between receptor residues and ligands across three independent simulations. DTPA[Ch-DE]₂ consistently exhibited more favorable (i.e., more negative) binding energies than AV-45, indicating higher thermodynamic stability. These pronounced energy minima suggest potential binding hotspots and

Table 2. Docking results of the best-docked conformation using AutoDock Vina Software

Compounds	Binding affinity energy (kcal/mol)
DTPA[Ch-DE] ₂ with A β monomer	-3.6
DTPA[Ch-DE] ₂ with A β fibril	-5.7
DTPA[Ch-DM] ₂ with A β fibril	-5.2
Florbetapir (AV-45) with A β fibril	-4.0
PIB with A β fibril	-5.0




Figure 7. A) Fused PET/CT images taken 30 min p.i. of [^{68}Ga]Ga-DTPA[Ch-DE]₂, a) normal, b) AD rat, c) Fused PET/CT images taken 30 min p.i. of Florbetapir in AD rat for 10 min; B) Dynamic PET/CT images of AD rat up to 20 min p.i. of [^{68}Ga]Ga-DTPA[Ch-DE]₂; C) Time-activity curve of dynamic PET imaging for up to 20 min p.i. of [^{68}Ga]Ga-DTPA[Ch-DE]₂ in AD rat




Figure 8. 2D schematic representation of the interactions: A) DTPA[Ch-DE]₂, and B) AV-45 with Aβ₄₂ pentameric fibril (2BEG)




Figure 9. MD simulation results, A) Total non-bonded interaction energies (kcal/mol) between ligands and receptor residues, averaged across three replicates; B) Spatial force map between the DTPA[Ch-DE]₂ and receptor residues. Red and blue denote attractive and repulsive forces, respectively; C) Time-dependent changes in the radius of gyration (RoG) for the receptor alone (gray), receptor with AV₄₅ control (black), and receptor with the DTPA[Ch-DE]₂ (orange). The plot illustrates structural compactness over a 100 ns simulation period, with RoG values (Å) on the y-axis and simulation time (ns) on the x-axis.; D) Root Mean Square Fluctuation (RMSF) analysis of Aβ₄₂ fibril chains (A–E) for the DTPA[Ch-DE]₂ compared to the control (AV-45). The plot highlights fluctuations at specific residues, including Gly 29, Asn 27, and Ser 26, with residue numbers indicated along the x-axis. RMSF values (y-axis) reflect the flexibility of the protein backbone across the evaluated regions

reflect the enhanced electrostatic complementarity of the DTPA[Ch-DE]₂ with the receptor. Figure 9B illustrates the force distribution across receptor residues interacting with the DTPA[Ch-DE]₂. Red regions (-8 to -5 kcal/mol.Å) highlight residues forming strong attractive interactions. The RoG analysis in Figure 9C evaluates the structural compactness of the receptor in three states: the unbound receptor, the receptor bound to the control compound (AV-45), and the receptor bound to the DTPA[Ch-DE]₂. The results indicate that both ligands have a similar effect on the RoG of the receptor, as their trajectories closely overlap over the last 100 ns of the simulation period. As can be seen, for the unbound receptor, the RoG fluctuates between ~14.1–14.7 Å, reflecting the inherent flexibility of the protein in its free state. However, in the presence of the ligands (both DTPA[Ch-DE]₂ and AV-45 compound), the RoG values reduce slightly (~0.2 Å) and remain within the same range with no significant deviation. This suggests that AV-45 binding does not induce major structural compaction or expansion.

The RMSF analysis (Figure 9D) reveals critical differences in local flexibility between the AV-45-bound and DTPA[Ch-DE]₂-bound receptor systems, despite their similar effects on global compactness (RoG: Figure 9C). These residue-specific variations provide valuable insights into ligand-induced dynamic changes. Both compounds show comparable RMSF profiles for most of the receptor structure (residues 13–130), with fluctuations typically below 2 Å, indicating generally stable secondary structural elements. However, a moderate difference was observed at residue Gly29, where DTPA[Ch-DE]₂ showed higher RMSF (~6 Å) compared to AV-45 (~4 Å). Of note, Gly29 resides within the naturally flexible turn region (residues 25–29) of the Aβ fibril, and elevated RMSF in this loop does not necessarily indicate enhanced binding. The adjacent region (residues 26–27, containing Asn27 and Ser26) also displays increased mobility with DTPA[Ch-DE]₂, though to a lesser degree. Moreover, molecular docking and MD simulations indicate that DTPA[Ch-DE]₂ exhibits superior binding performance compared to AV-45 florbetapir. This is evidenced by stronger interaction energies, favorable force distributions, and enhanced receptor stabilization (Figure 9). The results of force distribution highlight residues involved in strong attractive interactions Aβ fibril with the DTPA[Ch-DE]₂. For instance, Glu22 likely engages in π-π stacking or hydrophobic interactions, contributing significantly to binding affinity. Tryptophan, due to its rigid structure, may restrict ligand motion, enhancing complex stability. Additionally, polar residues such as Glu22 may form hydrogen bonds, aiding adaptive ligand orientation. In contrast, Lys28 exhibits weak repulsive forces (~0–1 kcal/mol.Å), likely due to electrostatic or steric effects. These forces might result from the carboxylate group of Lys28 interacting unfavorably with negatively charged or bulky moieties on the ligand. The RoG analysis demonstrates that both the control (AV-45) and DTPA[Ch-DE]₂ do not significantly alter the receptor's structural compactness.

The lack of significant RoG variation suggests that the binding of these ligands primarily influences local interactions (e.g., side-chain rearrangements or binding pocket dynamics) rather than large-scale structural reorganization. Since DTPA[Ch-DE]₂ mimics the effect of the control (AV-45), it may share a similar binding mode or induce comparable dynamic restraints on the receptor.

These computational results support the hypothesis that DTPA[Ch-DE]₂ maintains the receptor's native conformational flexibility - a feature that may be functionally advantageous for its intended therapeutic role. To further characterize these effects, additional investigations were performed on local structural perturbations through RMSF analysis. The RMSF analysis provides residue-level insights into the dynamic changes induced by ligand binding. This higher-resolution analysis complements the global perspective offered by the RoG measurements and helps identify specific regions of the receptor that may be functionally important for compound optimization.

The notable point in the RMSF analysis is that the multi-chain structure shows consistent RMSF patterns across chains (A-E), suggesting the observed flexibility changes are inherent to the protein's structural response rather than chain-specific artifacts. From a structural and functional perspective, RMSF analysis revealed that both DTPA[Ch-DE]₂ and AV-45 maintain generally similar flexibility profiles across most residues of the Aβ fibril (residues 13–130), with fluctuations typically below 2 Å. However, a notable difference was observed at Gly29 and adjacent residues (Ser26, Asn27), where DTPA[Ch-DE]₂ exhibited moderately higher RMSF (~6 Å) compared to AV-45 (~4 Å). Structurally, Gly29 is located within the turn region connecting the β-strands of the Aβ fibril (residues 25–29). This segment is inherently flexible due to the absence of stabilizing side-chain interactions and its role in allowing β-strand registration. Therefore, the increased RMSF observed for DTPA[Ch-DE]₂ does not necessarily indicate superior binding. Instead, it likely reflects that DTPA[Ch-DE]₂ engages the fibril through interactions that permit—or do not restrict—the natural conformational sampling of this loop region.

The preserved global stability (RoG) alongside localized flexibility changes implies that the DTPA[Ch-DE]₂ maintains overall receptor architecture while permitting specific functional motions, potentially generating distinct dynamic signatures that could influence allosteric communication. Notably, while both ligands maintain similar global receptor stability (RoG, Figure 9C), their RMSF profiles reveal key differences: AV-45 stabilizes specific local regions more effectively, whereas DTPA[Ch-DE]₂ allows greater local flexibility in particular structural elements, particularly at Gly29 and adjacent residues, suggesting divergent binding mechanisms despite comparable overall structural impacts. The combination of preserved global structure with targeted local flexibility modifications suggests DTPA[Ch-DE]₂ may offer novel functional properties while maintaining the receptor's

overall architectural integrity. These differences likely reflect unique binding interactions of DTPA[Ch-DE]₂ that could be leveraged for therapeutic optimization.

Conclusion

[⁶⁸Ga]Ga-DTPA[Ch-DE]₂ was successfully prepared with high radiochemical yield and purity. The radiotracer exhibited high stability against HSA and good binding affinity to Aβ aggregations in vitro binding assay and the brain sections of AD rats. The findings of biodistribution and imaging studies highlighted the favorable pharmacokinetic behavior of [⁶⁸Ga]Ga-DTPA[Ch-DE]₂, such as its ability to pass through BBB and slow washout from the brain of AD rats over time. Molecular docking and MD simulation confirmed the binding affinity and key interactions involved between DTPA[Ch-DE]₂ and Aβ fibrils. These findings demonstrate that [⁶⁸Ga]Ga-DTPA[Ch-DE]₂ could be a promising PET radiotracer for imaging Aβ plaques in AD.

Acknowledgements

The authors are grateful to the staff of the Nuclear Medicine Service of Shariati Hospital for their assistance with PET/CT acquisition. We also appreciate the support of Pars Isotope company for providing the ⁶⁸Ge/⁶⁸Ga PARS-GalloGEN generator and the florbetapir precursor.

Authors' Contribution

Conceptualization: Davood Beiki, Mehdi Akhlaghi, Safura Jokar
Data curation: All authors
Formal analysis: Zahra Ghiamaty, Omid Bavi, Hooman Hafezi, Omid Sabzevari, Mohammad Sharifzadeh, Mahboobeh Asadi, Tahereh Ghorbandaeipour
Investigation: Zahra Ghiamaty, Sara Roustaei, Mahshid Kian, Omid Sabzevari, Mohammad Sharifzadeh, Mahboobeh Asadi, Tahereh Ghorbandaeipour
Methodology: Davood Beiki, Mehdi Akhlaghi
Project administration: Davood Beiki
Resources: Davood Beiki
Software: Omid Bavi, Hooman Hafezi, Fatemeh Ebrahimi
Supervision: Davood Beiki, Mehdi Akhlaghi
Validation: Mehdi Akhlaghi, Safura Jokar, Mehdi Shafiee Ardestani
Visualization: Zahra Ghiamaty, Sara Roustaei, Mahshid Kiani
Writing—original draft: Zahra Ghiamaty, Safura Jokar
Writing—review & editing: All authors

Competing Interest

The authors declare no conflict of interest.

Data Availability Statement

All data will be available under request.

Ethical Approval

The study was approved by the ethics committee of Tehran University of Medical Sciences (Tehran, Iran) under Approval Code: IR.TUMS.TIPS.REC.1398.172.

Funding

This research was a part of a Ph.D. thesis and supported by Tehran University of Medical Sciences, Tehran, Iran [grant no. 98-3-412-45557].

Supplementary Files

Supplementary file contains ¹H NMR, FT-IR, and HRMS-ESI spectra as well as HPLC chromatograms of synthesized compounds

(Figures S1-S9).

References

1. Parle M, Balhara P, Kaura S. The mystery and history of Alzheimer's disease. *Int J Pharm Sci Res* 2023;14(7):3231-7. doi:[http://doi.org/10.13040/IJPSR.0975-8232.14\(7\).3231-37](http://doi.org/10.13040/IJPSR.0975-8232.14(7).3231-37)
2. World Health Organization (WHO). The Top 10 Causes of Death. WHO; 2024. Available from: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Accessed October 28, 2025.
3. Gustavsson A, Norton N, Fast T, Frölich L, Georges J, Holzapfel D, et al. Global estimates on the number of persons across the Alzheimer's disease continuum. *Alzheimers Dement* 2023;19(2):658-70. doi:[10.1002/alz.12694](https://doi.org/10.1002/alz.12694)
4. Liss JL, Seleri Assunção S, Cummings J, Atri A, Geldmacher DS, Candela SF, et al. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. *J Intern Med* 2021;290(2):310-34. doi:[10.1111/joim.13244](https://doi.org/10.1111/joim.13244)
5. Kurtakoti AU, Hiremath ND, Patil NS, Rane A. Benefits of early detection of Alzheimer's disease—a machine learning with image processing approach. *J Comput Theor Nanosci* 2020;17(1):378-83. doi:[10.1166/jctn.2020.8678](https://doi.org/10.1166/jctn.2020.8678)
6. Jokar S, Khazaei S, Behnammanesh H, Shamloo A, Erfani M, Beiki D, et al. Recent advances in the design and applications of amyloid-β peptide aggregation inhibitors for Alzheimer's disease therapy. *Biophys Rev* 2019. doi:[10.1007/s12551-019-00606-2](https://doi.org/10.1007/s12551-019-00606-2)
7. Thal DR, Poesen K, Vandenbergh R, De Meyer S. Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers. *Mol Neurodegener* 2025;20(1):33. doi:[10.1186/s13024-025-00819-y](https://doi.org/10.1186/s13024-025-00819-y)
8. Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, et al. The amyloid-β pathway in Alzheimer's disease: a plain language summary. *Neurodegener Dis Manag* 2023;13(3):141-9. doi:[10.2217/nmt-2022-0037](https://doi.org/10.2217/nmt-2022-0037)
9. Svedberg MM, Rahman O, Hall H. Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease. *Nucl Med Biol* 2012;39(4):484-501. doi:[10.1016/j.nucmedbio.2011.10.007](https://doi.org/10.1016/j.nucmedbio.2011.10.007)
10. Wang J, Jin C, Zhou J, Zhou R, Tian M, Lee HJ, et al. PET molecular imaging for pathophysiological visualization in Alzheimer's disease. *Eur J Nucl Med Mol Imaging* 2023;50(3):765-83. doi:[10.1007/s00259-022-05999-z](https://doi.org/10.1007/s00259-022-05999-z)
11. Pietrzak K, Czarnecka K, Mikiciuk-Olasik E, Szymanski P. New perspectives of Alzheimer disease diagnosis - the most popular and future methods. *Med Chem* 2018;14(1):34-43. doi:[10.2174/1573406413666171002120847](https://doi.org/10.2174/1573406413666171002120847)
12. Rasmussen J, Langerman H. Alzheimer's disease - why we need early diagnosis. *Degener Neurol Neuromuscul Dis* 2019;9:123-30. doi:[10.2147/dnnd.S228939](https://doi.org/10.2147/dnnd.S228939)
13. Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syvänen S. Antibody-based PET imaging of amyloid-β in mouse models of Alzheimer's disease. *Nat Commun* 2016;7:10759. doi:[10.1038/ncomms10759](https://doi.org/10.1038/ncomms10759)
14. Barrios-Lopez B, Raki M, Bergström K. Radiolabeled peptides for Alzheimer's diagnostic imaging: mini review. *Curr Radiopharm* 2013;6(4):181-91. doi:[10.2174/18744710066613112622835](https://doi.org/10.2174/18744710066613112622835)
15. Jokar S, Behnammanesh H, Erfani M, Sharifzadeh M, Gholami M, Sabzevari O, et al. Synthesis, biological evaluation and preclinical study of a novel ^{99m}Tc-peptide: a targeting probe of amyloid-β plaques as a possible diagnostic agent for Alzheimer's disease. *Bioorg Chem* 2020;99:103857. doi:[10.1016/j.bioorg.2020.103857](https://doi.org/10.1016/j.bioorg.2020.103857)
16. Guselnikova VV, Antimonova OI, Fedorova EA, Shavlovsky MM, Safray AE, Rukavishnikova AA, et al. A novel method for amyloid detection in human tissue load using a fluorescent dye - Congo red analogue. *Sovrem Tekhnologii Med*

- 2020;12(1):65-70. doi:[10.17691/stm2020.12.1.08](https://doi.org/10.17691/stm2020.12.1.08)
17. Needham LM, Weber J, Pearson CM, Do DT, Gorka F, Lyu G, et al. A comparative photophysical study of structural modifications of thioflavin T-inspired fluorophores. *J Phys Chem Lett* 2020;11(19):8406-16. doi:[10.1021/acs.jpcclett.0c01549](https://doi.org/10.1021/acs.jpcclett.0c01549)
 18. Dezutter NA, Landman WJ, Jager PL, de Groot TJ, Dupont PJ, Tooten PC, et al. Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. *Amyloid* 2001;8(3):202-14. doi:[10.3109/13506120109007363](https://doi.org/10.3109/13506120109007363)
 19. Schlein E, Syvänen S, Rokka J, Gustavsson T, Rossin R, Robillard M, et al. Functionalization of radiolabeled antibodies to enhance peripheral clearance for high contrast brain imaging. *Mol Pharm* 2022;19(11):4111-22. doi:[10.1021/acs.molpharmaceut.2c00536](https://doi.org/10.1021/acs.molpharmaceut.2c00536)
 20. Baig MH, Ahmad K, Rabbani G, Choi I. Use of peptides for the management of Alzheimer's disease: diagnosis and inhibition. *Front Aging Neurosci* 2018;10:21. doi:[10.3389/fnagi.2018.00021](https://doi.org/10.3389/fnagi.2018.00021)
 21. Molavipordanjani S, Emami S, Hosseinimehr SJ. 99mTc-labeled small molecules for diagnosis of Alzheimer's disease: past, recent and future perspectives. *Curr Med Chem* 2019;26(12):2166-89. doi:[10.2174/0929867325666180410104023](https://doi.org/10.2174/0929867325666180410104023)
 22. Newberg AB, Wintering NA, Plössl K, Hochold J, Stabin MG, Watson M, et al. Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. *J Nucl Med* 2006;47(5):748-54.
 23. Myburgh PJ, Solingapuram Sai KK. Two decades of [11C]PiB synthesis, 2003-2023: a review. *Am J Nucl Med Mol Imaging* 2024;14(1):48-62. doi:[10.62347/adsk6584](https://doi.org/10.62347/adsk6584)
 24. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, et al. 2-(2-[2-Dimethylaminothiazol-5-yl] ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. *J Nucl Med* 2007;48(4):553-61. doi:[10.2967/jnumed.106.037556](https://doi.org/10.2967/jnumed.106.037556)
 25. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease β -amyloid with [11C]SB-13 PET. *Am J Geriatr Psychiatry* 2004;12(6):584-95. doi:[10.1176/appi.ajgp.12.6.584](https://doi.org/10.1176/appi.ajgp.12.6.584)
 26. Cole GB, Satyamurthy N, Liu J, Wong KP, Small GW, Huang SC, et al. The value of in vitro binding as predictor of in vivo results: a case for [18F]FDDNP PET. *Mol Imaging Biol* 2019;21(1):25-34. doi:[10.1007/s11307-018-1210-2](https://doi.org/10.1007/s11307-018-1210-2)
 27. Theriault J, Benedet AL, Pascoal TA, Savard M, Ashton NJ, Chamoun M, et al. Determining amyloid- β positivity using 18F-AZD4694 PET imaging. *J Nucl Med* 2021;62(2):247-52. doi:[10.2967/jnumed.120.245209](https://doi.org/10.2967/jnumed.120.245209)
 28. Soffers F, Ceyssens S, Buffet W, de Surgeleuse D, Crols R. 18F-florbetapir PET in primary cerebral amyloidoma. *Clin Nucl Med* 2020;45(10):838-9. doi:[10.1097/rlu.0000000000003214](https://doi.org/10.1097/rlu.0000000000003214)
 29. Collij LE, Farrar G, Zwan M, van de Giessen E, Ossenkoppeler R, Barkhof F, et al. Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population. *Alzheimers Res Ther* 2023;15(1):207. doi:[10.1186/s13195-023-01351-1](https://doi.org/10.1186/s13195-023-01351-1)
 30. Kang H, Kang DY. Alzheimer's disease prediction using attention mechanism with dual-phase 18F-florbetaben images. *Nucl Med Mol Imaging* 2023;57(2):61-72. doi:[10.1007/s13139-022-00767-1](https://doi.org/10.1007/s13139-022-00767-1)
 31. Ono M, Haratake M, Mori H, Nakayama M. Novel chalcones as probes for in vivo imaging of β -amyloid plaques in Alzheimer's brains. *Bioorg Med Chem* 2007;15(21):6802-9. doi:[10.1016/j.bmc.2007.07.052](https://doi.org/10.1016/j.bmc.2007.07.052)
 32. Nelson BJ, Andersson JD, Wuest F, Spreckelmeyer S. Good practices for 68Ga radiopharmaceutical production. *EJNMMI Radiopharm Chem* 2022;7(1):27. doi:[10.1186/s41181-022-00180-1](https://doi.org/10.1186/s41181-022-00180-1)
 33. Uğur A. Chemistry, production and application relationship of galyum-68 used in nuclear medical imaging. In: Cetindere S, ed. *Natural Sciences: Methods and Applications*. Ankara: Iksad Publications; 2021. p. 39-56.
 34. Chauhan K, Datta A, Adhikari A, Chuttani K, Kumar Singh A, Mishra AK. 68Ga based probe for Alzheimer's disease: synthesis and preclinical evaluation of homodimeric chalcone in β -amyloid imaging. *Org Biomol Chem* 2014;12(37):7328-37. doi:[10.1039/c4ob00941j](https://doi.org/10.1039/c4ob00941j)
 35. Wang XQ, Zhou LY, Tan RX, Liang GP, Fang SX, Li W, et al. Design, synthesis, and evaluation of chalcone derivatives as multifunctional agents against Alzheimer's disease. *Chem Biodivers* 2021;18(11):e2100341. doi:[10.1002/cbdv.202100341](https://doi.org/10.1002/cbdv.202100341)
 36. Karimi-Zandi L, Ghorbandaiepour T, Zahmatkesh M. The increment of annexin V-positive microvesicles versus annexin V-negative microvesicles in CSF of an animal model of Alzheimer's disease. *Neurosci Lett* 2023;814:137446. doi:[10.1016/j.neulet.2023.137446](https://doi.org/10.1016/j.neulet.2023.137446)
 37. Paxinos G, Watson C. *The Rat Brain in Stereotaxic Coordinates*. 7th ed. Elsevier Science; 2014. p. 547-612.
 38. Jokar S, Erfani M, Bavi O, Khazaei S, Sharifzadeh M, Hajiramezanali M, et al. Design of peptide-based inhibitor agent against amyloid- β aggregation: molecular docking, synthesis and in vitro evaluation. *Bioorg Chem* 2020;102:104050. doi:[10.1016/j.bioorg.2020.104050](https://doi.org/10.1016/j.bioorg.2020.104050)
 39. Bavi N, Cox CD, Nikolaev YA, Martinac B. Molecular insights into the force-from-lipids gating of mechanosensitive channels. *Curr Opin Physiol* 2023;36:100706. doi:[10.1016/j.cophys.2023.100706](https://doi.org/10.1016/j.cophys.2023.100706)
 40. Bavi N, Martinac AD, Cortes DM, Bavi O, Ridone P, Nomura T, et al. Structural dynamics of the MscL C-terminal domain. *Sci Rep* 2017;7(1):17229. doi:[10.1038/s41598-017-17396-w](https://doi.org/10.1038/s41598-017-17396-w)
 41. Ghadirian F, Abbasi H, Bavi O, Naeimabadi A. How living cells are affected during the cold atmospheric pressure plasma treatment. *Free Radic Biol Med* 2023;205:141-50. doi:[10.1016/j.freeradbiomed.2023.06.002](https://doi.org/10.1016/j.freeradbiomed.2023.06.002)
 42. Jamali M, Bavi O. Aquaporin channels in desalination: mechanical properties and operational load analysis. *Desalination* 2025;594:118245. doi:[10.1016/j.desal.2024.118245](https://doi.org/10.1016/j.desal.2024.118245)
 43. Emamgholipour Z, Dabirian S, Peytam F, Saeedian Moghadam E, Firoozpour L, Safavi M, et al. Synthesis, biological evaluation, and in silico study of novel coumarin-quinazoline analogs as potential anti-angiogenesis agents. *Results Chem* 2024;11:101819. doi:[10.1016/j.rechem.2024.101819](https://doi.org/10.1016/j.rechem.2024.101819)
 44. Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer's disease: epidemiology and clinical progression. *Neurol Ther* 2022;11(2):553-69. doi:[10.1007/s40120-022-00338-8](https://doi.org/10.1007/s40120-022-00338-8)
 45. Capponi PC, Mari M, Ferrari E, Asti M. Radiolabeled chalcone derivatives as potential radiotracers for β -amyloid plaques imaging. *Molecules* 2023;28(7):3233. doi:[10.3390/molecules28073233](https://doi.org/10.3390/molecules28073233)
 46. Rampa A, Bartolini M, Pruccoli L, Naldi M, Iriepa I, Moraleda I, et al. Exploiting the chalcone scaffold to develop multifunctional agents for Alzheimer's disease. *Molecules* 2018;23(8):1902. doi:[10.3390/molecules23081902](https://doi.org/10.3390/molecules23081902)
 47. Thapa P, Upadhyay SP, Suo WZ, Singh V, Gurung P, Lee ES, et al. Chalcone and its analogs: therapeutic and diagnostic applications in Alzheimer's disease. *Bioorg Chem* 2021;108:104681. doi:[10.1016/j.bioorg.2021.104681](https://doi.org/10.1016/j.bioorg.2021.104681)
 48. Fu M, Ji C, Yang T, Mao F, Shati AA, El-Kott AF, et al. Anti-ovarian cancer potential, in silico studies, and anti-Alzheimer's disease effects of some natural compounds as cholinesterase inhibitors. *Biotechnol Appl Biochem* 2023;70(3):1085-99. doi:[10.1002/bab.2422](https://doi.org/10.1002/bab.2422)
 49. Ono M, Hori M, Haratake M, Tomiyama T, Mori H, Nakayama

- M. Structure-activity relationship of chalcones and related derivatives as ligands for detecting of β -amyloid plaques in the brain. *Bioorg Med Chem* 2007;15(19):6388-96. doi:[10.1016/j.bmc.2007.06.055](https://doi.org/10.1016/j.bmc.2007.06.055)
50. Sobek J, Li J, Combes BF, Gerez JA, Henrich MT, Geibl FF, et al. Efficient characterization of multiple binding sites of small molecule imaging ligands on amyloid- β , tau and α -synuclein. *Eur J Nucl Med Mol Imaging* 2024;51(13):3960-77. doi:[10.1007/s00259-024-06806-7](https://doi.org/10.1007/s00259-024-06806-7)
 51. Duan P, Chen KJ, Wijegunawardena G, Dregni AJ, Wang HK, Wu H, et al. Binding sites of a positron emission tomography imaging agent in Alzheimer's β -amyloid fibrils studied using ^{19}F solid-state NMR. *J Am Chem Soc* 2022;144(3):1416-30. doi:[10.1021/jacs.1c12056](https://doi.org/10.1021/jacs.1c12056)
 52. Tanase T. Introduction: what is a metal complex? In: Tanase T, Ishii Y, eds. *Coordination Chemistry: Molecular Science of Organic-Inorganic Complexes*. Vol 3. London: Royal Society of Chemistry;2024.p.1-12. doi:[10.1039/9781837673254-00001](https://doi.org/10.1039/9781837673254-00001)
 53. Spang P, Herrmann C, Roesch F. Bifunctional gallium-68 chelators: past, present, and future. *Semin Nucl Med* 2016;46(5):373-94. doi:[10.1053/j.semnuclmed.2016.04.003](https://doi.org/10.1053/j.semnuclmed.2016.04.003)
 54. Tsionou MI, Knapp CE, Foley CA, Munteanu CR, Cakebread A, Imberti C, et al. Comparison of macrocyclic and acyclic chelators for gallium-68 radiolabelling. *RSC Adv* 2017;7(78):49586-99. doi:[10.1039/c7ra09076e](https://doi.org/10.1039/c7ra09076e)
 55. Mann G, Chauhan K, Kumar V, Daksh S, Kumar N, Thirumal M, et al. Bio-evaluation of $^{99\text{m}}\text{Tc}$ -labeled homodimeric chalcone derivative as amyloid- β -targeting probe. *Front Med (Lausanne)* 2022;9:813465. doi:[10.3389/fmed.2022.813465](https://doi.org/10.3389/fmed.2022.813465)
 56. Kaide S, Ono M, Watanabe H, Shimizu Y, Nakamoto Y, Togashi K, et al. Conversion of iodine to fluorine-18 based on iodinated chalcone and evaluation for β -amyloid PET imaging. *Bioorg Med Chem* 2018;26(12):3352-8. doi:[10.1016/j.bmc.2018.05.001](https://doi.org/10.1016/j.bmc.2018.05.001)
 57. Li W, Zha X, Zhang X, Dai H, Pu S, Yao X, et al. Enhanced positron emission tomography imaging of β -amyloid through focused ultrasound-mediated gallium-68 radiotracer delivery across the blood-brain barrier. *ACS Chem Neurosci* 2025;16(15):3070-81. doi:[10.1021/acscchemneuro.5c00476](https://doi.org/10.1021/acscchemneuro.5c00476)
 58. Saha GB, MacIntyre WJ, Go RT. Radiopharmaceuticals for brain imaging. *Semin Nucl Med* 1994;24(4):324-49. doi:[10.1016/s0001-2998\(05\)80022-4](https://doi.org/10.1016/s0001-2998(05)80022-4)
 59. Velikyan I. Prospective of ^{68}Ga -radiopharmaceutical development. *Theranostics* 2013;4(1):47-80. doi:[10.7150/thno.7447](https://doi.org/10.7150/thno.7447)